---
title: Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment
nct_id: NCT07118813
overall_status: RECRUITING
sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
study_type: OBSERVATIONAL
primary_condition: Renal Cell Carcinoma (Kidney Cancer)
countries: China
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT07118813.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT07118813"
ct_last_update_post_date: 2025-08-12
last_seen_at: "2026-05-12T06:08:16.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment

**Official Title:** Application of Radiomics-based AI Models in Predicting Clinical Outcome of Patients With Renal Cell Carcinoma After Surgical Treatment (AI-Kidney-Prognosis)

**NCT ID:** [NCT07118813](https://clinicaltrials.gov/study/NCT07118813)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 400
- **Lead Sponsor:** Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- **Conditions:** Renal Cell Carcinoma (Kidney Cancer)
- **Start Date:** 2025-08
- **Completion Date:** 2026-08
- **CT.gov Last Update:** 2025-08-12

## Brief Summary

This is a prospective observational cohort study (AI-Kidney-Prognosis), aiming to non-invasively predict the clinical outcomes in renal cell carcinoma patients after surgical treatment using radiomics-based AI models, thereby assisting clinical decision-making and personalized follow-up strategies.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

1. Patients were treated for renal cell carcinoma in Wuhan Union Hospital from August 2025 to August 2026;
2. Aged \> 18 years old;
3. At least one abdominal CT scan before treatment;
4. Tissue biopsy pathological examination confirmed the diagnosis of renal cell carcinoma.

Exclusion Criteria:

1. Poor image quality;
2. Incomplete clinical data or loss of follow-up;
3. Presence of another primary malignancy other than renal cell carcinoma;
4. Unclear pathological diagnosis.
```

## Primary Outcomes

- **Progression-free survival** _(time frame: 1 year)_

## Locations (1)

- Union Hospital，Tongji Medical College，Huazhong University of Science and Technology, Wuhan, Hubei, China — _RECRUITING_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.union hospital，tongji medical college，huazhong university of science and technology|wuhan|hubei|china` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT07118813.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT07118813*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*